Shree Ganesh Remedies Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹630 Cr
Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects. FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs.
From Shree Ganesh Remedies Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹508
Market Cap
₹630 Cr
P/E Ratio
40.8
How does Shree Ganesh Remedies Ltd rank in Pharmaceuticals & Biotechnology?
Compare Shree Ganesh Remedies Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
- →Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects.
- →Revenue is expected to double over the next 3-4 years, driven largely by CRAMS and new projects.
- →CRAMS revenue will increase steadily, potentially doubling or tripling in the future.
- →No single project contributes ₹100 crore currently; peak revenues for key projects are around ₹30-35 crore annually.
- →Larger scale projects with volumes above 200-500 metric tons are in the pipeline, supporting growth.
- →FY26 is expected to be a consolidation year with moderate top-line growth and margin normalization.
- →CRAMS commercialization and approvals anticipated to support commercial supplies starting from mid-FY26 onwards.
- →Base business (pharma intermediates and specialty chemicals) projected to grow at mid-teens CAGR over the medium term.
- →Investments in R&D, capacity-building, and new chemistries are aligned with anticipated project demands to support future scale-up.
📈 Profitability & Margins
- →FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs.
- →Revenue growth is projected at a moderate pace rather than drastic increase in FY26.
- →Over the next 3-4 years, revenue is expected to double driven by growth in CRAMS projects and new product commercialization with a targeted CAGR of 20-25%.
- →New large-scale CRAMS projects with high-volume (>200 tons) and customer-specific custom synthesis are key growth drivers.
- →Infrastructure and R&D investments are anticipated to enable accelerated and profitable growth beyond FY26.
- →Profitability will improve as new manufacturing capacities become better utilized and higher margin CRAMS volumes ramp up.
- →EPS growth will follow revenue and margin expansion as commercial supplies from CRAMS projects commence, especially in FY27-29 timeframe.
🏗️ Capital Expenditure Plans
- →The company has invested significantly in R&D, infrastructure, and capacity over the last two years, focusing on projects they anticipate will commercialize in the near future.
- →CapEx remains aggressive with ongoing construction of manufacturing Block 9 near Plant 8, and a new pilot plant near Plant 4 to support advanced chemistries including flow chemistry.
- →Planned CapEx for FY26 is approximately ₹15 crore, mainly for manufacturing blocks and pilot plant.
- →Development of common infrastructure and utilities at the Dahej site is underway to support large-scale CRAMS projects.
- →Expansion at the Ankleshwar site is preferred for manufacturing infrastructure with ample space after acquiring neighboring land.
- →Strategic investment supports new technologies and equipment necessary for complex specialty chemical projects, including flow and other advanced chemistries.
- →A 2.5 MW solar power park was recently commissioned, contributing up to 70% of electricity from renewable sources, underlining commitment to sustainable manufacturing.
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned fundraising through debt or equity in the transcript.
- →The company is funding its strategic investments, including infrastructure and capacity expansions, through internal accruals.
- →The focus is on operational consolidation and capacity building in FY26 with approximate CapEx of around ₹15 crore.
- →No indications were given about raising external capital; emphasis is on financial prudence and using internal resources for growth initiatives.
📋 Order Book & Pipeline
- →The company is actively working on multiple custom synthesis (crams) projects, with 6 projects typically closed in the lab annually.
- →Current crams revenue is approximately 15-20% of total revenue, expected to grow steadily over the next few years.
- →The order book includes projects with peak volumes above 200 metric tons; e.g., agrochemical and Japanese projects targeting 250-500+ metric tons.
- →New innovative multi-step complex products are in development with a few projects expected to generate annual revenues of 30-35+ crore at peak.
- →No single project currently expected to add 100 crore in FY27; growth anticipated through a portfolio of small-to-medium projects.
- →FY26 is seen as a consolidation year with capacity building and approvals underway, preparing for commercial supply ramp-up in FY27-28.
- →The Dahej site is being developed with utilities and infrastructure to support large-scale projects as firm orders materialize.
Key Metrics
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q4 FY25 results?
Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects. FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 40.8 with a market cap of ₹630 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
The company has invested significantly in R&D, infrastructure, and capacity over the last two years, focusing on projects they anticipate will commercialize in the near future.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.